Orange Book product · Brand (NDA)
THYQUIDITY
LEVOTHYROXINE SODIUM
At a glance
Nov 30, 2020
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 30, 2020
5 yr 8 mo ago
Today
Patent 9050307 expires
Listed drug product patent expiration.
Aug 06, 2031
in 5 yr 2 mo
Pharmaceutical detail
Active ingredient
LEVOTHYROXINE SODIUM
Strength
100MCG/5ML
Dosage form
SOLUTION
Route
ORAL
TE code
Not listed
Application
NDA 214047
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2022ERMEZABrand (NDA)
NDA 215809 · MYLAN
- 2021LEVOTHYROXINE SODIUMBrand (NDA)
NDA 214253 · HIKMA
- 2019LEVOTHYROXINE SODIUMBrand (NDA)
NDA 210632 · FRESENIUS KABI USA
- 2016TIROSINT-SOLBrand (NDA)
NDA 206977 · IBSA
- 2011LEVOTHYROXINE SODIUMBrand (NDA)
NDA 202231 · FRESENIUS KABI USA
- 2007TIROSINTBrand (NDA)
NDA 021924 · IBSA
- 2003LEVOLETBrand (NDA)
NDA 021137 · GENUS LIFESCIENCES
- 2002THYRO-TABSBrand (NDA)
NDA 021116 · ALVOGEN
- 2002SYNTHROIDBrand (NDA)
NDA 021402 · ABBVIE
- 2002EUTHYROXBrand (NDA)
NDA 021292 · EMD SERONO INC
- 2002LEVO-TBrand (NDA)
NDA 021342 · CEDIPROF INC
- 2001LEVOXYLBrand (NDA)
NDA 021301 · KING PHARMS
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9050307 | Aug 06, 2031 | in 5 yr 2 mo | Product |

